3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
2265
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1734
Leukemia
1500
Leukemia, Lymphocytic, Chronic, B-Cell
1120
Myelodysplastic Syndromes
963
Hematologic Neoplasms
935
Lymphoma
739
Lymphoma, Non-Hodgkin
654
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
532
Multiple Myeloma
501
Lymphoma, Follicular
467
Hodgkin Disease
460
Lymphoma, Mantle-Cell
459
Burkitt Lymphoma
440
Lymphoma, Large B-Cell, Diffuse
433
Lymphoma, B-Cell, Marginal Zone
402
Recurrence
356
Leukemia, Myelomonocytic, Chronic
351
Myeloproliferative Disorders
330
Leukemia, Myeloid, Chronic-Phase
311
Lymphoma, Large-Cell, Immunoblastic
303
Congenital Abnormalities
273
Neoplasms
271
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
249
Blast Crisis
246
Leukemia, Myeloid, Accelerated Phase
244
Primary Myelofibrosis
221
Neoplasms, Plasma Cell
220
Waldenstrom Macroglobulinemia
216
Lymphoma, T-Cell, Cutaneous
197
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Purpura, Thrombotic Thrombocytopenic
×
Other hematologic neoplasm
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn